Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control Study. Cancers 2021;13:4584 (SCI;IF=6.639; ONCOLOGY 51/242)
A pilot study examining the relationship between environmental contaminants and colorectal cancer at a single medical institute in Taiwan. 台灣衛誌;40:382-393 (non SCI)
Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure.Frontiers in Oncology. 2021;11:68334 (SCI;IF=6.244; ONCOLOGY 62/242)
The efficacy and toxicity of adjuvant S-1 schedule with 2-week administration followed by 1-week rest in gastric cancer patients. Journal of Gastrointestinal Oncology. 2021;12:297-306. (SCI;IF= 2.892; GASTROENTEROLOGY & HEPATOLOGY 70/92)
Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib. PEERJ 2020;8:e10382 (SCI;IF=2.984; MULTIDISCIPLINARY SCIENCES 27/73)
Elevated neutrophil-to-lymphocyte ratio and predominance of intrahepatic cholangiocarcinoma prediction of poor hepatectomy outcomes in patients with combined hepatocellular-cholangiocarcinoma.PLOS ONE. 2020;15:24079 (SCI;IF=3.240; MULTIDISCIPLINARY SCIENCES 26/73)
Development and validation of a prognostic nomogram to predict survival in patients with advanced pancreatic cancer receiving second-line palliative chemotherapy. Journal of Gastroenterology and Hepatology. 2020;35:1694-1703 (SCI;IF=4.029; GASTROENTEROLOGY & HEPATOLOGY 45/92)
External validation of the Besancon nomogram in Asian patients with advanced pancreatic cancer receiving second-line chemotherapy: A multi-institute experience in Taiwan. Pancreatology. 2020;20:116-124 (SCI;IF=3.996; GASTROENTEROLOGY & HEPATOLOGY 46/92)
Efficacy and Safety of Uracil Tegafur in Patients with Recurrentor Metastatic Thymic Carcinoma.台灣癌症醫學會雜誌.20207:111-115 (non SCI)
Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West. PLOS ONE. 2020;15:23000 (SCI;IF=3.240; MULTIDISCIPLINARY SCIENCES 26/73)
Effect of S?1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7?year multicenter observational cohort study in Taiwan. Cancer Medicine. 2019;8:2085-2094. (SCI;IF=4.452; ONCOLOGY 107/242)
Lung Metastases in Patients with Stage IV Pancreatic Cancer: Prevalence, Risk Factors, and Survival Impact. Journal of Clinical Medicine. 2019;8:e1402 4.241. (SCI;IF=4.241,MEDICINE, GENERAL & INTERNAL 39/168)
Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy. Cancer Medicine. 2019;8:5554-5563. 4.452; (SCI;IF=4.452,ONCOLOGY 107/242)
Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model. Cancers. 2019;11:57 (SCI;IF=6.639; ONCOLOGY 51/242)
Presence of Chronic Obstructive Pulmonary Disease (COPD) Impair Survival in Lung Cancer Patients Receiving Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI): A Nationwide, Population-Based Cohort Study. Journal of Clinical Medicine. 2019;8:1024 4.241. (SCI;IF=4.241;MEDICINE, GENERAL & INTERNAL 39/168)
Association of time interval between cancer diagnosis and initiation of palliative chemotherapy with overall survival in patients with unresectable pancreatic cancer. Cancer Medicine. 2019;8:3471-3478 (SCI;IF=4.452; ONCOLOGY 107/242)
Evolution of the chemotherapeutic landscape and survival outcome in patients with metastatic pancreatic cancer: a four-institute cohort study inTaiwan, 2010–2016. Cancer Management and Research 2019;11:2119-2127 (SCI, IF=3.989; ONCOLOGY 128/242)
MET RON dual inhibitor, BMS 777607, suppresses cholangiocarcinoma cell growth, and MET RON upregulation indicates worse prognosis for intra hepatic cholangiocarcinoma patients. Oncology Reports. 2018;40:1411-1421 (SCI,IF=3.906; ONCOLOGY 133/242)
Venous Thromboembolism in Asian Patients with Pancreatic Cancer Following Palliative Chemotherapy: Low Incidence but a Negative Prognosticator for Those with Early Onset. Cancers. 2018;10:501 (SCI;IF=6.639; ONCOLOGY 51/242)
YIncidence, Risk Factors, and Outcomes of Arterial Thromboembolism in Patients with Pancreatic Cancer Following Palliative Chemotherapy. Cancers. 2018;10:432 (SCI;IF=6.639; ONCOLOGY 51/242)
Hydroxysteroid 11-Beta Dehydrogenase 1 Overexpression with Copy-Number Gain and Missense Mutations in Primary Gastrointestinal Stromal Tumors. Journal of Clinical Medicine. 2018;7:408 (SCI;IF=4.241; MEDICINE, GENERAL & INTERNAL 39/168)
Role of PLK1 signaling pathway genes in gastrointestinal stromal tumors. Oncology Letters. 2018;16:3070-3082. (non-SCI)
SIRT1 overexpression is an independent prognosticator for patients with esophageal squamous cell carcinoma.Journal of Cardiothoracic Surgery. 2018;13:25 (SCI;IF=1.637; CARDIAC & CARDIOVASCULAR SYSTEM 123/141)
Positive expression of Midkine predicts early recurrence and poor prognosis of initially resectable combined hepatocellular cholangiocarcinoma. BMC CANCER.2018;18:227.(SCI;IF= 4.430; ONCOLOGY 109/242)
A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17. Oncotarget.2017;8:44121-44130. (non-SCI)
Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of Imatinib.Clinical Cancer Research. 2017;23:4908-4918 (SCI;IF=12.531; ONCOLOGY 18/242)
PLCB4 copy gain and PLCs4 overexpression in primary gastrointestinal stromal tumors: Integrative characterization of a lipid-catabolizing enzyme associated with worse disease-free survival. Oncotarget 2017;8:19997-20010. (non-SCI)
Surgical management of patients with progressing metastatic gastrointestinal stromal tumors receiving sunitinib treatment: A prospective cohort study.International journal of surgery. 2017;39:30-36 (SCI;IF=6.071; SURGERY 15/211)
Transcriptomic reappraisal identifies MGLL overexpression as an unfavorable prognosticator in primary gastrointestinal stromal tumors. Oncotarget.2016;7:49986-49997. (non-SCI)
The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan. Asia-Pacific Journal of Clinical Oncology.2016;12:396-402 (SCI;IF=2.601; ONCOLOGY 199/242)
A Prognostic Nomogram for Overall Survival of Patients After Hepatectomy for Intrahepatic Cholangiocarcinoma. Anticancer research. 2016;36:4249-4258 (SCI;IF=2.480; ONCOLOGY 209/242)
Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder. Journal of Cancer. 2016;7:1347-1352 (SCI;IF=4.207; ONCOLOGY 119/242)
Prognostic model to predict survival in patients with metastatic upper tract urothelial carcinoma treated with cisplatin-based chemotherapy. International Journal of Urology. 2016;23:385-389 (SCI; IF= 3.369; UROLOGY & NEPHROLOGY 36/90)
Modifiable Prognostic Factors of Hepatocellular Carcinoma in Patients with Non-Surgical Treatment. PLOS ONE 2015;10:14489 (SCI; IF= 3.240; MULTIDISCIPLINARY SCIENCES 26/73
The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy.Urologic oncology-seminars and original investigations. 2015 Nov; 33(11) : 495.e9-495.e14 (SCI; IF= 3.498; UROLOGY & NEPHROLOGY 32/90)
Peritumoral SPARC expression and patient outcome with resectable intrahepatic cholangiocarcinoma. Oncotargets and therapy. 2015;8:1899-1907 4.147. (SCI; IF= 4.147;BIOTECHNOLOGY & APPLIED MICROBIOLOGY 53/159)
Feasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib.Medicine 2015;94:1-6. (SCI; IF= 1.889; MEDICINE, GENERAL & INTERNAL 99/168)
Multiple Endocrine Neoplasia Type 1 With GastricNeuroendocrine Tumor Presented With Gastric Polyposis. Clinical Gastroenterology and Hepatology. 2015;13:e45 11.382; (SCI; IF=11.382; GASTROENTEROLOGY & HEPATOLOGY 8/92)
Fractioned dose regimen of sunitinib for patients with gastrointestinal stromal tumor: a pharmacokinetic and treatment efficacy study. Translational Oncology. 2014;7:620-625. (SCI; IF=4.243; Oncology 117/242)
Intra-arterial chemotherapy with doxorubicin and cisplatin is effective for advanced hepatocellular cell carcinoma. Scientific world journal. 2014:16013.(non-SCI)
Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumors. Oncotarget. 2014;5:4071-4086. (non-SCI)
Metastatic Urothelial Carcinoma of the Bladder with Lymph Node-only Metastasis Treated with M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) has a Better Survival than GC (Gemcitabine and Cisplatin). 中華民國癌症醫學會雜誌. 2014;1:197-207. (non-SCI)
AMACR amplification and overexpression in primary imatinib-naive gastrointestinal stromal tumors: a driver of cell proliferation indicating adverse prognosis. Oncotarget. (non-SCI) 2014;5:11588-11603.
Imatinib Escalation or Sunitinib Treatment After First-line Imatinib in Metastatic Gastrointestinal Stromal Tumor Patients. Anticancer research. 2014;34:5029-5036. (SCI; IF=2.480; Oncology 209/242)
Post-mastectomy radiotherapy benefits subgroups of breast cancer patients with T1–2 tumor and 1–3 axillary lymph node(s) metastasis. Radiology and Oncology. 2014;48:314-322. (SCI; IF=2.991; Radiology, Nuclear medicine & Medical imaging 65/134)
Fas/Fas Ligand Mediates Keratinocyte Death in Sunitinib-Induced Hand-Foot Skin Reaction. Journal of investigative dermatology. 2014; 134: 2768 -2775. (SCI; IF=8.551; Dermatology 4/68)
HuR cytoplasmic expression is associated with increased cyclin A expression and inferior disease-free survival in patients with gastrointestinal stromal tumours (GISTs). Histopathology. 2013;63:445-454. (SCI; IF=5.087; Pathology 18/77)
Brain Metastasis in Patients with Esophageal Squamous Cell Carcinoma: A Single Institute Experience in Southern Taiwan. 中華民國癌症醫學會雜誌. 201329:182-189. (non-SCI)
Integrating bioinformatics and clinicopathological research of gastrointestinal stromal tumors: identification of aurora kinase A as a poor risk marker. Annals of Surgical Oncology 2012;19:3491-3499. (SCI; IF=5.344; Onocology 81/242)
Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers. Experimental and Therapeutic Medicine. 2012 Aug; 4(2): 231–236 (SCI; IF=2.447; Medcine, Research & Experimental 104/140)
A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer. Gastric Cancer 2012;15:49-55. (SCI; IF=7.370; Gastroenterology & hepatology 18/92)
Imatinib mesylate for patients with recurrent or metastatic gastrointestinal stromal tumors expressing kit : A decade experience from Taiwan. Translational oncology. 2011 ; 4:328-325. (SCI; IF=3.393; Oncology 97/184)
A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer. Gastric cancer. 2012;15:49-55. (SCI; IF=1.897; Gastroenterology & hepatology 44/71)
Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance. World journal of gastroenterology.2011;17:2113-2119. (SCI; IF=1.897; Gastroenterology & hepatology 35/71)
Pemetrexed as third-line chemotherapy for locally advanced and metastatic non-small cell lung cancer (NSCLC) : A retrospective analysis.2011;27:157-164
Chen YH, Lu HI, Huang CH, Rau KM, Chiu YC, Wang YM, Chen YY, Liu CT, Li SH*.The use of trimodality treatment of locally advanced resectable esophageal squamous cell carcinoma: a single institute experience in southern Taiwan. Journal of Cancer Research and Practice. 2011; Oct 27(5): 200-210
